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Conclusions: In patients with type 2 diabetes and stable coronary
artery disease (CAD), a strategy of prompt revascularization with intensive
medical therapy is no better than intensive medical therapy alone with
respect to rates of death, myocardial infarction, or stroke.
Summary: The Bypass Angioplasty Revascularization Investigation 2
Diabetes (BARI 2D) trial assessed treatment strategies in patients with CAD
and diabetes. Because of the uncertainty of the effects of coronary revascu-
larization in patients with type 2 diabetes and the uncertainty of how to
deliver glycemic control in such patients, the authors evaluated two cardiac
treatment strategies and two glycemic treatment strategies in patients receiv-
ing glycemic control and intensive therapy for stable CAD. There were two
hypotheses. The first was that prompt revascularization would reduce long-
term rates of death and cardiovascular events compared withmedical therapy
alone. The second was that insulin-sensitization with a targeted hemoglobin
A1C level of7.0% would reduce cardiovascular events and death compared
with a strategy of insulin-provision.
There were 2,368 patients with type 2 diabetes and CAD assigned to
undergo prompt revascularization with intensive medical therapy or inten-
sive medical therapy alone and to receive either insulin-provision therapy or
insulin-sensitization therapy. Primary end points were rates of death, a
composite of death andmyocardial infarction, or stroke. Randomization was
stratified according to whether percutaneous coronary intervention (PCI) or
coronary artery bypass grafting (CABG) was considered the most appropri-
ate intervention for the patient’s CAD.
At 5 years, survival rates did not differ between the revascularization
groups (88.3%) and the medical therapy alone group (87.8%, P  .97).
Furthermore, survivor rates did not differ between the insulin-sensitization
group (88.2%) and the insulin-provision group (87.9%, P  .89). Freedom
from major cardiovascular events was not different in the revascularization
group (77.2%) vs the medical therapy group (75.9%, P  .70). There was
also no difference in freedom from major cardiovascular events in the
insulin-sensitization group (77.7%) vs the insulin-provision group (75.4%, P
.13). In the patient stratum of PCI, there was no significant difference
between the revascularization group and the medical therapy group in the
rates of the primary end points. In the CABG stratum, the rate of major
cardiovascular events was 30.5% in themedical therapy group vs 22.4% in the
revascularization group (P .01). Serious adverse events and adverse events
were similar among groups, with the exception that severe hyperglycemia
was more frequent in the insulin-provision group than in the insulin-
sensitization group (9.2% vs 5.9%, P  .003).
Comment: The results of this study once again highlight the difficulty
of achieving improvement in cardiovascular event rates in patients with type
2 diabetes. Previous studies have shown tight glycemic control does not
improve cardiovascular event rates in patients with type 2 diabetes (N Engl
J Med 2008;358:2560-72; N Engl J Med 2008;358:2545-59). This study
indicates prompt revascularization in patients with type 2 diabetes also
treated with intensive medical therapy does not improve rates of death from
any cause or major cardiovascular event rates. In patients in whom CABG
would be the preferred treatment of revascularization, CABG does appear
able to reduce major cardiovascular event rates compared with medical
therapy alone. However, if coronary angioplasty was felt to be the revascu-
larizationmethod of choice, it did not improve death inmajor cardiovascular
event rates compared with medical therapy alone. It appears the era of the
“ocular stenotic reflex” for coronary artery angioplasty is drawing to a close.
It needs to draw to a close for lesions in other vascular beds as well.
C-Reactive Protein-Bound Enzymatically Modified Low-Density Li-
poprotein Does Not Transform Macrophages into Foam Cells
Singh SK, Suresh MV, Prayther DC, et al. J Immunology 2008;180:4316-
4322.
Conclusions: C-reactive protein (CRP) can prevent the formation of
foam cells and may influence atherogenesis.
Summary: Atherosclerosis is a complicated process that appears to begin
when low-density lipoprotein (LDL) enters an arterial wall. Trapped LDL is
sensitive to modifications such as enzymatic proteolysis and oxidation. When
LDL is enzymatically modified (E-LDL), it can be engulfed bymacrophages to
form foam cells that subsequently contribute to the development of atheroscle-
rosis. One strategy of decreasing atherosclerosis is therefore to capture and
inactivate LDL, thereby preventing the formation of macrophage foam cells.
CRP is a pentameric protein made of five identical 23,028 Dalton subunits.
700Each subunit has a phosphocholine binding site. Amino acids in the phospho-
choline binding site ofCRParePhe66 andGlu81.Thephosphocholine binding
site of CRP participates in bonding of CRP to modified forms of LDL.
This study of CRP-LDL interactions specifically focused on the forma-
tion of macrophage foam cells by unbound and CRP-bound LDL. The
authors found phosphocholine inhibited interactions between CRP and
E-LDL, implying involvement of the phosphocholine binding site of CRP in
binding to E-LDL. The amino acids Phe66 and Glu81 were not required for
CRP–E-LDL interaction. Blocking the CRP phosphocholine binding site
with phosphoethanolamine increased the binding of CRP to E-LDL. CRP-
bound E-LDL did not transform macrophages into foam cells, whereas free
E-LDL did transform macrophages into foam cells. Blocking the binding of
phosphoethanolamine increased binding of CRP to E-LDL. The function of
CRP in eliminating the ability of E-LDL to form foam cells was not impaired
by phosphoethanolamine.
Comment: The data lead to two conclusions: First, phosphoethano-
lamine can potentiate the binding of CRP to enzymatically modified LDL.
This can increase the efficiency of CRP to prevent the transformation of
macrophages into LDL foam cells. The authors’ findings also suggest that if
CRP is present in sufficient amounts in an arterial wall and if each LDL
molecule entering the arterial wall is bound to CRP, it may be possible that
CRP can, when present in sufficient amounts in the arterial wall, be capable
of preventing foam cell formation and thereby provide a targetingmethod to
prevent atherosclerosis.
Comparison of Interventional Outcomes According to Preoperative
Indication: A Single Center Analysis of 2,240 Limb Revascularizations
Taylor SM, Cull DL, Kalbaugh CA, et al. J AmColl Surg 2009;208:770-80.
Conclusion: Patients undergoing leg revascularization with tissue loss
have significantly worse outcomes than those patients undergoing leg revas-
cularization for ischemic rest pain.
Summary: The authors correctly point out that frequently in an
analysis of revascularizations for critical limb ischemia (CLI), patients with
tissue loss and ischemic rest pain are combined in the analysis. The authors
hypothesize that combining such patients for assessment of both graft-
related and patient-related outcomesmay be inappropriate in that one group
may fare worse than the other. Rather than stratify their results according to
the level of peripheral arterial disease such as aortoiliac or infrainguinal, or
the method of revascularization—open vs endovascular surgery—they
sought to stratify results according to indication for procedure: claudication,
ischemic rest pain, and tissue loss. They evaluated the outcomes of 2240
consecutive limb revascularizations in 1732 patients from January 1998
through December 2005. The patients were stratified and examined accord-
ing to preoperative indication: claudication (999 limbs), ischemic rest pain
(464 limbs), or tissue loss (777 limbs). Their end points included primary
and secondary interventional or operative patency, limb salvage, survival,
amputation-free survival, maintenance of independence, maintenance of
ambulation, and resolution of presenting symptoms. There was a mean
follow-up of 1089 days (range, 0-3689 days).
Overall outcomes at 5 years declined according to indication for
intervention—claudication, rest pain, or tissue loss—for all end points
measured, including secondary reconstruction patency (93%, 80%, 66%,
respectively; P  .001), limb salvage (99%, 81%, 68%, respectively; P 
.001), survival (78%, 46%, 30%, respectively; P  .001), amputation-free
survival (78%, 42%, 25%, respectively; P  .001), maintenance of ambula-
tion (96%, 78%, 68%, respectively; P  .001), maintenance of indepen-
dence (98%, 85%, 75%, respectively; P .001), and resolution of presenting
symptoms (79%, 61%, 42%, respectively; P  .001).
Comment: The authors chose an unusual method of analyzing their
results of lower extremity revascularization. The concept of analyzing results
according to indication for operation seems reasonable, and the conclusion
that patients with tissue loss do worse than those patients with ischemic rest
pain is likely correct. Nevertheless, the article would have been strengthened
by a more proper statistical analysis, stratifying patients according to method
of revascularization (endovascular, autogenous vein, or prosthetic grafts)
and level of revascularization (aortoiliac, femoropopliteal, or infrapopliteal).
As written, the results are useful for analyzing the practice pattern at the
authors’ institution, but without proper multivariable analysis, the results
cannot be extrapolated to other institutions where practice patterns likely
differ.
